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Primary congenital glaucoma (PCG) is a rare but severe 
form of glaucoma that can lead to blindness from the infantile 
period. The characteristic findings of PCG include the classic 
triad of presenting symptoms in the newborn: epiphora, 
photophobia, and blepharospasm [1]. Elevated intraocular 
pressure (IOP) causes optic atrophy in the late stage. The 
incidence of PCG varies from country to country depending 
on ethnicity. The highest incidence (1 in 1,250) occurs in the 
Slovakian Romani population with higher rates of consan-
guinity, while lower incidence (1 in 18,500 to 1 in 30,000) 
is observed in Western populations [2,3]. The prevalence in 
the Han Chinese population is approximately 1 in 5,000 to 
1 in 25,000 (1 in 10,000 on average) [4]. Several genetic loci 
have been linked to PCG in family linkage studies, including 
GLC3A (Gene ID: 1545, OMIM #: 601771; 2p22-p21) [5], 
GLC3B (Gene ID: 2728, OMIM #: 600975; 1p36.2-p36.1) 
[6], GLC3C (gene ID: 399565, OMIM #: 613085; l4q24.2-
q24.3) [7], and GLC3D (Gene ID: 4053, OMIM #: 602091; 
14q24) [8,9]. Two genes have been identified from these loci: 
CYP1B1, coding for cytochrome P450, family 1, subfamily B, 
polypeptide 1 at GLC3A [10], and LTBP2, coding for latent 
transforming growth factor-β-binding protein 2 at GLC3D 
[8,9].
Previous studies showed that mutations in CYP1B1 are 
the predominant cause of PCG [11,12]. Populations with a 
higher mutation frequency of CYP1B1 in patients with PCG 
often possess a higher incidence of PCG. For instance, Arab 
and Romani populations have the highest incidence of PCG, 
corresponding to the highest mutation frequency of CYP1B1 
in patients with PCG (90% to 100%) [13]. However, in our 
previous study, only 17.2% of patients with PCG had CYP1B1 
mutations in a Han Chinese population [14], corresponding 
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Purpose: To identify deleterious mutations in the latent transforming growth factor-β–binding protein 2 (LTBP2) gene 
in sporadic patients with primary congenital glaucoma (PCG) from a Han Chinese population, which had been excluded 
for mutations in the CYP1B1 gene.
Methods: In this retrospective case–control study, 36 coding exons and adjacent exon–intron boundaries of LTBP2 
were amplified with PCR and screened for mutations with Sanger sequencing in DNA samples of 214 sporadic patients 
with PCG. Sequence variants identified in the patients with PCG were subsequently screened in 100 unaffected control 
subjects and the unaffected parents of the patients with PCG who had sequence changes in LTBP2.
Results: Eight heterozygous single nucleotide polymorphisms (SNPs) in coding regions of LTBP2 were identified in the 
patients with PCG. Four of these SNPs were missense changes that resulted in the replacement of amino acids (rs2304707, 
rs116914994, rs45468895, and rs763035721), two of which (rs2304707 and rs116914994) were also present in the control 
subjects. No significant differences in the frequencies of the missense SNPs were found between the patients with PCG 
and the controls. The two missense SNPs, rs45468895 and rs763035721, which were each found in one patient also existed 
in their unaffected parents, suggesting that these two SNPs were not segregated in these families and are unlikely to be 
a disease-causative variant. In addition, four synonymous SNPs were detected in the patients with PCG (rs61738025, 
rs862031, rs199805158, and rs12586758).
Conclusions: The results showed that no deleterious mutations were found in coding regions of LTBP2 in patients with 
PCG, suggesting that it is not a causal gene for PCG in the Han Chinese population.
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to the lower incidence of PCG in the Han Chinese population 
[4]. The low frequencies of CYP1B1 mutations in patients 
with PCG from some populations [14,15] indicate that PCG 
is genetically heterogeneous, and other genes may contribute 
to the disease.
The GLC3C locus spans a region of around 5.77 Mb that 
contains more than 40 genes, and it has been confirmed and 
further mapped within a genetic distance of 0.006 cM [16]. 
LTBP2 is around 1.3 Mb proximal to the GLC3C locus [8,9]. 
Ocular expression studies have determined the presence of 
LTBP2 in the trabecular meshwork and ciliary processes 
[17]. Recently, LTBP2 has been verified as essential for the 
development of ciliary zonule microfibrils [18]. Several 
studies have shown that LTBP2 mutations are associated with 
secondary glaucoma [19-22]. Null mutations have been found 
in patients with PCG from Pakistani, Iranian, and Slovakian 
Romani consanguineous families [8,9,23]. However, the exact 
role of LTBP2 in the development of PCG remains unclear. 
Several studies did not discover any deleterious mutations in 
LTBP2 in sporadic PCG North Indian, British, and American 
cases [24-26]. Intriguingly, a possible role of LTBP2 has been 
suggested in the etiology of primary open angle glaucoma 
(POAG), primary angle closure glaucoma (PACG), and 
secondary glaucoma, such as megalocornea, spherophakia, 
ectopia lentis, Weill-Marchesani syndrome, and pseudoex-
foliation syndrome [19-22,27,28]. In the present study, we 
screened for mutations in the LTBP2 gene in a large sample 
of Chinese patients with PCG, aiming to evaluate the role of 
LTBP2 in Chinese patients with PCG.
METHODS
Study subjects: A total of 214 unrelated patients diagnosed 
with PCG but without mutations in the CYP1B1 gene were 
included in this study [14,29]. Briefly, we amplified the 
coding regions (exons 2 and 3) and the promoter region of 
CYP1B1 with PCR and screened for CYP1B1 mutations with 
direct sequencing with forward and reverse primers [14,29]. 
PCR was performed in a 25 µl mixture containing genomic 
DNA (50 ng), forward and reverse primers (0.5 µmol/l), 
magnesium chloride (1.5 mmol/l), deoxyribonucleotide 
triphosphate (dNTP; 0.2 µmol/ml) and Taq polymerase (1 U; 
Takara Bio Inc, Shiga, Japan), as per the following proce-
dure: initial denaturation at 95 °C for 5 min, 35 cycles of 
denaturation at 94 °C for 45 s, annealing at a primer-specific 
temperature for 45 s, extension at 72 °C for 1 min and a final 
extension at 72 °C for 10 min. We excluded patients who 
carried CYP1B1 mutations from the present study. Among 
these sporadic cases, 152 trios that consisted of one affected 
proband and two unaffected parents had been used in our 
previous study of GLC3C with the transmission disequilib-
rium test (TDT) [16]. As the other 62 sporadic cases had only 
one parent available for genotyping, they were excluded from 
TDT in our previous study [16]. The diagnosis of PCG was 
based on the following criteria [29]: 1) Age of diagnosis was 
less than 3 years old, 2) the cornea was enlarged so that the 
parameter was bigger than 11 mm or edema with or without 
Haab striae, 3) IOP was greater than 21 mmHg, and 4) the cup 
to disk ratio was enlarged or dissymmetric between two eyes. 
Patients with other ocular or systemic anomalies, such as 
aniridia, anterior segment dysgenesis, congenital hereditary 
endothelial dystrophy, neurofibromatosis, and Sturge–Weber 
syndrome, were excluded.
All patients underwent comprehensive examinations of 
the anterior segments with slit-lamp and surgical microscope, 
the structure of anterior chamber angles with gonioscope, and 
the ocular fundus with a direct ophthalmoscope. IOP was 
measured with Tono- PEN® (Reichert, Depew, NY) before or 
during surgery under general anesthesia. Corneal opacity was 
scored based on the microscope examination, and a higher 
corneal opacity score indicated a more opaque cornea [29]. 
The more severe eye was recorded and analyzed when cases 
were bilateral present.
One hundred ethnically matched unrelated individuals 
without any ocular or systemic disorders were enrolled as 
controls. The unaffected parents of the patients with PCG 
who had sequence changes in LTBP2 were also included in 
the study. All the controls and healthy parents were older than 
18 years and had normal IOP, open angles on gonioscopy, and 
normal optic nerves on ocular fundus examination. Peripheral 
blood samples were collected from patients and controls by 
venipuncture in EDTA vacutainers and stored in −20 °C until 
further use.
All study subjects were Han Chinese who live in Main-
land China. This study adhered to the ARVO statement on 
human subjects. This study was approved by the Ethics 
Committee of the Eye and ENT hospital, Fudan Univer-
sity. Informed written consent was obtained from all study 
subjects after explanation of the nature and possible conse-
quences of the study, in accordance with the tenets of the 
Declaration of Helsinki.
Screening for LTBP2 mutations with Sanger sequencing: 
DNA extraction and Sanger sequencing were performed for 
all 214 patients with PCG using standard methods [30]. The 
primers were designed to include the intron–exon boundaries 
of LTBP2 using the software Primer Premier 5.0 (Table 1). 
Standard PCR conditions were run to amplify all exons and 
exon–intron boundaries of LTBP2. PCR was performed in 
a 25 µl mixture containing genomic DNA (50 ng), forward 
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and reverse primers (0.5 µmol/l), magnesium chloride (1.5 
mmol/l), deoxyribonucleotide triphosphate (dNTP; 0.2 µmol/
ml) and Taq polymerase (1 U; Takara Bio Inc, Shiga, Japan), as 
per the following procedure: initial denaturation at 95 °C for 
5 min, 35 cycles of denaturation at 94 °C for 45 s, annealing 
at a primer-specific temperature for 45 s, extension at 72 °C 
for 1 min and a final extension at 72 °C for 10 min. All PCR 
products were analyzed on 2% agarose gel and stained with 
ethidium-bromide (EB, 10 mg/ml). Then the right size prod-
ucts were purified with spin-columns technology (QIAQuick 
PCR Purification Kit; Qiagen, Valencia, CA). Using ABI 
BigDye chemistry (Applied Biosystems Inc., Foster City, 
CA), Sanger sequencing was performed on the PCR ampli-
cons and was processed through an automated ABI 3730 
XL Sequencer (Applied Biosystems). The sequences were 
scrutinized for variations alongside reference sequences from 
the University of California, Santa Cruz Genome Browser 
website using Sequencher 5.0 software (Gene Codes, Ann 
Arbor, MI). PCR and Sanger sequencing were subsequently 
performed on 100 unaffected control samples with identified 
sequence variants. The unaffected parents of the patients with 
PCG who had sequence changes in LTBP2 were also screened 
for the specific SNPs using Sanger sequencing. The PCR 
products were first sequenced with forward primers. Further 
sequencing with reverse primers was performed to confirm 
the identified variants.
Statistical analysis: Fisher’s exact test was used to compare 
the allele frequencies of the LTBP2 variants between patients 
with PCG and controls. A Bonferroni corrected p value of 
0.0125 was considered statistically significant.
RESULTS
Clinical features of the patients: Some clinical features of the 
patients with PCG in this study are shown in Figure 1. At the 
preoperative examination, the median IOP was 36 mmHg, 
with an average corneal diameter of 13.5 mm. The median 
age of diagnosis was 4.5 months, ranging from birth to 3 
years old. The median corneal opacity score was 2, indicating 
mild corneal haze with visible iris. Figure 2 shows the classic 
clinical features seen in the left eye of a patient with PCG.
Screening for LTBP2 mutations: Eight single nucleotide 
polymorphisms (SNPs) were identified in the coding regions 
of the LTBP2 gene in the patients with PCG. All these vari-
ants were inherited in a heterozygous manner. Four missense 
SNPs resulted in the replacement of amino acids (rs2304707, 
rs116914994, rs45468895, and rs763035721, Table 2). Two of 
the SNPs, rs2304707 and rs116914994, which changed amino 
acids p.Pro319Gln and p.Arg1429Gln, respectively, were also 
present in the control subjects. No significant differences in 
the frequencies of these missense SNPs were found between 
the patients with PCG and the controls. The other two 
missense SNPs, rs45468895 and rs763035721, which changed 
amino acids p.Ala1204Val and p.Glu1794Lys, respectively, 
were each found in one patient with PCG. Their unaffected 
parents also had the same sequence changes, suggesting 
that these two SNPs were not segregated in these families 
and, thus, were unlikely to be a disease-causative variant. 
In addition, four synonymous SNPs were detected in the 
patients with PCG (rs61738025, rs862031, rs199805158, and 
rs12586758).
DISCUSSION
Null mutations in LTBP2 were initially found to cause PCG in 
four consanguineous families from Pakistan and in patients 
of Romani ethnicity [8]. Subsequently, mutations in LTBP2 
were identified in patients with PCG from several other popu-
lations, such as Iranian and Slovakian Romani families (Table 
3) [9,23]. However, several other studies did not discover 
deleterious mutations in LTBP2 in sporadic North Indian, 
British, and American patients with PCG [24-26]. In the 
present study, we screened 214 sporadic patients with PCG 
from the Han Chinese population for mutations in the LTBP2 
gene. We did not find disease-causative mutations in LTBP2 
in the patients with PCG, which is consistent with previous 
studies [24-26]. None of the previously reported pathogenic 
mutations was detected in our study (Table 3) [8,9,23]. In 
addition, the SNP rs2304707 identified in this study was also 
reported as a polymorphism in consanguineous Iranian fami-
lies with PCG and a Turkish GLC3C-linked family with PCG 
[9,25]. Another SNP rs862031 has been reported in patients in 
the United States [26]. None of the other SNPs identified in 
the present study was reported in patients with PCG in other 
populations [8,9,23].
In addition to PCG, LTBP2 has been related to the 
development of secondary glaucoma, such as megalocornea, 
spherophakia, ectopia lentis, Weill-Marchesani syndrome, 
and pseudoexfoliation syndrome [19,21,22,27]. This can be 
well explained by recent findings in Ltbp2–/– mice [18]. 
The mice survived to adulthood but developed lens luxa-
tion caused by compromised ciliary zonule formation. The 
suppression of LTBP2 expression in cultured human ciliary 
epithelial cells by siRNA disrupted the formation of the 
microfibril meshwork by the cells [18]. Supplementation of 
recombinant LTBP2 in culture medium not only rescued 
the microfibril meshwork formation in LTBP2-suppressed 
ciliary epithelial cells but also restored unfragmented and 
bundled ciliary zonules in Ltbp2 –/– mouse eyes under organ 
culture [18]. The LTBP proteins are important components 
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of the extracellular matrix (ECM) that interact with fibrillin 
microfibrils and have several different roles in microfibril 
biology. There are four LTBP isoforms in the human genome 
(LTBP-1, -2, -3, and -4). LTBP-2 is expressed abundantly in 
elastic tissues and unique in the family as it is the only one 
that does not bind to latent transforming growth factor-beta 
(TGF-β) [31]. Several reports indicate that LTBP-2 has a role 
in the elastic fiber assembly process, especially fibrillin-1 and 
-2 [18,32]. Whether increased IOP is a primary symptom or 
a secondary effect of another abnormality caused by LTBP2 
mutations in childhood glaucoma remains controversial.
In summary, we screened for mutations in the LTBP2 
gene in a large sample of Chinese patients with PCG. We did 
not detect deleterious mutations in LTBP2, suggesting that 
this gene is not a causal gene for PCG in the Han Chinese 
population.
Table 1. PCR PRimeRs used foR amPlifiCaTion of LTBP2 gene.
Primer name Forward Primer Reverse Primer Product size (bp)
Exon1 GGGAGAGATGAAAGCAGGCAAGG AGGTGGAGGCAGCCAGCAGA 350
Exon2 CGTTCAAGTCATCACACTCATTCACA AAGGGCGAGGGTCCCAGCATT 666
Exon3 TGTGATAGTTTATGACGGAGTTGTTAGGG GCATTGAGGCAGAGCGGGAG 456
Exon3–5 CTCTGGCTTGGTGTGTCTTTCCC CAATGCCCCACCCTTTCCTG 1110
Exon5–6 GTGGATGTCGTGGTCAGGGAGGT GCTAGTCTTGAGAAGGAAATGATGGAG 982
Exon7 TGGGACAGAAAAGGTGGAGGC GTGACACTGAAAGAAGGGGAGAGA 289
Exon8 CGTCCAGGCTCCTTCCACAG TCTTGAGATGATGATTAGGCCACTT 559
Exon9 GGACACGCTCTCTGTAAACCTCTGA TGCCACTCCTCTCCTTTTTTCTTCT 100
Exon10–11 CCCCTGGGCGAGGAGTTGAA GGCAGTGGAGGAAAAGGAGTG 1027
Exon12 CATCTGTGGAAAGTGCTCTGCTC TCCCTGACTCTCCTATGGGCTACT 329
Exon13–14 CCTCACATCACTCCTCGCTCCC GCTGCCATCGGCTGTCTTCC 578
Exon15 AGAGGGGGCATCCCATTTGTATC AGGAGGAAAAGCCAGTCCCAGAG 354
Exon15–16 GGGGGCATCCCATTTGTATCCT CCTATTCACACTGACCCAACACATCC 789
Exon17 CATTCACCCAGTACCCGTTCTCAC GCCCACCGTCTTGGACTTCTCTC 488
Exon18 ACAACAGCCTCCAAGCCACCTCC GTCCATCCCTCTCCCCAACCAAA 344
Exon19 GCAACAGGGCGGAGGTTACAG GCAGACCCGAAGGGGATATAGTG 788
Exon20 ATTCTGCGGCACGGTGTTTG ACTGGGCTGACTTTATGGCTTCC 409
Exon21 ACTGCTTGGACCTTCTGCTTCTTC GGGGGATGCCCTACTATGACCT 465
Exon22 TTCCCCCTTCTGGGCTTGG GGCTTCACCCTTCGTTCTTGG 445
Exon23 TCTGATTTATGTGCTAAGTGGTGC GCTTCTGTTACTGTGTTGAGATGCT 654
Exon24 TCCGTGAGGTGGTTTGAGGC GGGCAGAGGCAGGTAAGAAGAGT 645
Exon25 ATGGAAGAGGAAGTGGGTGGGG ATGGGGCAGCGAGTGTGAGAA 710
Exon26 AAGCCAACAGCCAGAGGACAAAC TGGGGAGTCACGAGTCTCATCAAG 657
Exon27 TCCAGGTTGAATAGCCGACAC AAACTGAGGCACAGGGAGAGG 422
Exon28 GGCTGACTTGATTTCCCACCCTA TTTGTCTTTCTGTGCCTGTCTTATTTC 697
Exon29 GCTGGAACAGGAGGTAAGGAGATAA TGGCAGAATGTGGGGAGTGAG 626
Exon30 AACAAAGAGGACAGAGAGGAGGAGAAG TCAGAGGGTTGGAAATGAGGGTG 443
Exon31 TCCACCCAACTGGCACTCCTC CCAAGTCTGGCTTCCGCATCT 783
Exon32 AGAGAAACAGGCGGCAGAACC AAAATACCAACACTCAGCCATAGGA 897
Exon33 ATGATAGATTGGGCAGAAATAGAGC GTAGGGAGTAGGTACAGGACTTGGTT 846
Exon34 ATGCCAGGGAAAGCCAAGGA TGTGGGACGTGGTGGTGTGAG 680
Exon35 TGGGAGTAGGGTGGGGAATGG AGAAGGTGGGACTGTCGGAGGG 225
Exon36 GCCTGATGTCACGGTGTCTTCC GCTCCCTACAGCACTCTCCTTTG 281
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Figure 1. Clinical features of 
Chinese patients with primary 
congenital glaucoma.
Figure 2. Classic features of Chinese patients with primary congenital glaucoma. A: The left eye is obviously bigger than the right eye and 
mild corneal haze with visible iris. B: Intraocular pressure (IOP) was measured with Tono-PEN®. C,D: The horizontal diameter of the cornea 
is about 13 mm measured with bisecting compasses. E,F: The structure of the anterior chamber angle on gonioscopy; absence of angle recess; 
peripheral iris hypoplasia; tenting of the peripheral iris pigment epithelium. G,H: The fundi photos show a dissymmetric cup disc ratio.
Table 2. LTBP2 PolymoRPhisms idenTified fRom PaTienTs wiTh PRimaRy CongeniTal glauComa.
SNP ID Exon Sequence change Amino acid change
Minor allele frequency (%)
P value
Affected Unaffected
rs2304707 4 c.956C>A p. Pro319Gln 35/370 (9.5) 7/90 (7.8) 0.62
rs45468895 24 c.3611C>T p. Ala1204Val 1/428 (0.2) 0/200 (0.0) 0.49
rs116914994 29 c.4286G>A p. Arg1429Gln 22/428 (5.1) 16/200 (8.0) 0.16
rs763035721 36 c.5380G>A p. Glu1794Lys 1/428 (0.2) 0/200 (0.0) 0.49
Fisher’s exact test was used to compare the allele frequencies of the LTBP2 variants between PCG patients and controls. A Bonferroni 
corrected p value of 0.0125 was considered significant.
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